Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

Full Story